No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
WVE240517P7500
- 1.82
- 0.000.00%
15min DelayTrading Apr 11 10:33 ET
0.00High0.00Low
0.00Open1.82Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover5125.08%IV-11.11%PremiumMay 17, 2024Expiry Date1.11Intrinsic Value100Multiplier-5DDays to Expiry0.71Time Value100Contract SizeAmericanOptions Type-0.5989Delta0.1541Gamma3.51Leverage Ratio-22.2023Theta0.0000Rho-2.10Eff Leverage0.0002Vega
Intraday
- 5D
- 1D
News
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Wells Fargo Starts Wave Life Sciences at Buy, Cites Valuation
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on WAVE Life Sciences (NASDAQ:WVE) in the last three months.The table below summarizes their recent
WAVE Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 88.36% Wells Fargo → $11 Initiates Coverage On → Overweight 04/01/2024 191.1% Truist Securities
Express News | Wave Life Sciences Ltd : Wells Fargo Initiates With Overweight Rating; Price Target $11
Buy Rating on Wave Life Sciences: Promising Pipeline and Market Potential
Comments
$Wave Life Sciences(WVE.US$
NEWS
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Wave Life Sciences announces continued momentum in GSK collaboration with the selection of two programs for development, initiation of clinical trials for the INHBE program in obesity, and upcoming presentations at key conferences. GSK collaboration progresses with an aggregate initiation payment of $12 million for two oligonucleotide programs using Wav...
NEWS
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Wave Life Sciences announces continued momentum in GSK collaboration with the selection of two programs for development, initiation of clinical trials for the INHBE program in obesity, and upcoming presentations at key conferences. GSK collaboration progresses with an aggregate initiation payment of $12 million for two oligonucleotide programs using Wav...
Investors' optimism about strong revenue performance may have led to a high P/S ratio. However, with forecasted revenue decline, this high ratio may not be sustainable, posing a risk to shareholders and potential investors.
Wave Life Sciences Ltd.'s high P/S ratio may be worrisome due to expected revenue shrinkage. Current investors could face disappointment if the P/S ratio aligns with the negative growth forecast, putting their investments at risk and potential investors may overpay.
Company's low cash burn relative to market cap allows easy fund-raising for growth. Noteworthy decrease in cash burn, paired with significant revenue growth, shows solid spending control, easing concerns about cash burn.
$Wave Life Sciences(WVE.US$ Wave Life Sciences Q3 2023 EPS $0.07 Beats $(0.18) Estimate, Revenue $49.21M Beats $23.43M Estimate![]()
Read more